Friday, 16 October 2026European Markets

TIPIAK And KERRY GROUP PLC Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(vianews) - tipiak (tipi.pa) is among this list of stock assets with the highest dividend rate and return on equity on the consumer defensive sector.

financial asset price forward dividend yield return on equity
tipiak (tipi.pa) €58.00 2.8% 6.82%
kerry group plc (krz.ir) €89.48 1.22% 11.84%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. tipiak (tipi.pa)

2.8% forward dividend yield and 6.82% return on equity

tipiak société anonyme, a food company, manufactures prepared food products, frozen ready-meals, pastry products, groceries, and crusty bread products. the company offers groceries, such as breadcrumbs, cereals, couscous, croutons, japanese pearls, potato starch, quinoa, and tapioca; frozen products, including savory products, appetizers, and side dishes with grains; and frozen sweet products comprising macarons, mini eclairs, and petits fours. it sells its products in france, england, and the united states. the company was founded in 1830 and is based in saint-aignan-grandlieu, france.

earnings per share

as for profitability, tipiak has a trailing twelve months eps of €4.62.

pe ratio

tipiak has a trailing twelve months price to earnings ratio of 12.55. meaning, the purchaser of the share is investing €12.55 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.82%.

more news about tipiak.

2. kerry group plc (krz.ir)

1.22% forward dividend yield and 11.84% return on equity

kerry group plc, together with its subsidiaries, provides taste and nutrition solutions. the company operates in two segments, taste & nutrition and dairy ireland. the taste & nutrition segment offers taste and nutrition solutions for the food, beverage, and pharmaceutical markets. the dairy ireland segment provides value-add dairy ingredients and consumer products, including functional proteins and nutritional bases. it operates in ireland, rest of europe, the americas, the asia pacific, the middle east, and africa. kerry group plc was founded in 1972 and is headquartered in tralee, ireland.

earnings per share

as for profitability, kerry group plc has a trailing twelve months eps of €3.49.

pe ratio

kerry group plc has a trailing twelve months price to earnings ratio of 25.64. meaning, the purchaser of the share is investing €25.64 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.84%.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on oct 12, 2023, the estimated forward annual dividend rate is 1.08 and the estimated forward annual dividend yield is 1.22%.

volatility

kerry group plc's last week, last month's, and last quarter's current intraday variation average was a negative 0.97%, a positive 0.04%, and a positive 0.80%.

kerry group plc's highest amplitude of average volatility was 1.14% (last week), 0.92% (last month), and 0.80% (last quarter).

volume

today's last reported volume for kerry group plc is 12429 which is 95.01% below its average volume of 249487.

more news about kerry group plc.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com